Cargando…

A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction

(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Ipek, Emrah, Yolcu, Mustafa, Yildirim, Erkan, Altinkaynak, Konca, Ozbek Sebin, Saime, Kalkan, Kamuran, Gulcu, Oktay, Ermis, Emrah, Ozturk, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321077/
https://www.ncbi.nlm.nih.gov/pubmed/30501029
http://dx.doi.org/10.3390/ijms19123797
_version_ 1783385356175933440
author Ipek, Emrah
Yolcu, Mustafa
Yildirim, Erkan
Altinkaynak, Konca
Ozbek Sebin, Saime
Kalkan, Kamuran
Gulcu, Oktay
Ermis, Emrah
Ozturk, Mustafa
author_facet Ipek, Emrah
Yolcu, Mustafa
Yildirim, Erkan
Altinkaynak, Konca
Ozbek Sebin, Saime
Kalkan, Kamuran
Gulcu, Oktay
Ermis, Emrah
Ozturk, Mustafa
author_sort Ipek, Emrah
collection PubMed
description (1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.
format Online
Article
Text
id pubmed-6321077
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63210772019-01-07 A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction Ipek, Emrah Yolcu, Mustafa Yildirim, Erkan Altinkaynak, Konca Ozbek Sebin, Saime Kalkan, Kamuran Gulcu, Oktay Ermis, Emrah Ozturk, Mustafa Int J Mol Sci Article (1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI. MDPI 2018-11-29 /pmc/articles/PMC6321077/ /pubmed/30501029 http://dx.doi.org/10.3390/ijms19123797 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ipek, Emrah
Yolcu, Mustafa
Yildirim, Erkan
Altinkaynak, Konca
Ozbek Sebin, Saime
Kalkan, Kamuran
Gulcu, Oktay
Ermis, Emrah
Ozturk, Mustafa
A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title_full A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title_fullStr A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title_full_unstemmed A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title_short A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
title_sort novel marker of inflammation: azurocidin in patients with st segment elevation myocardial infarction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321077/
https://www.ncbi.nlm.nih.gov/pubmed/30501029
http://dx.doi.org/10.3390/ijms19123797
work_keys_str_mv AT ipekemrah anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT yolcumustafa anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT yildirimerkan anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT altinkaynakkonca anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ozbeksebinsaime anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT kalkankamuran anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT gulcuoktay anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ermisemrah anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ozturkmustafa anovelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ipekemrah novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT yolcumustafa novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT yildirimerkan novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT altinkaynakkonca novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ozbeksebinsaime novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT kalkankamuran novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT gulcuoktay novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ermisemrah novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction
AT ozturkmustafa novelmarkerofinflammationazurocidininpatientswithstsegmentelevationmyocardialinfarction